Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
Brief: Biohaven - Federal Court Confirms Ra Capital And Avilar Therapeutics "Misappropriated" Yale Trade Secret
Biohaven Ltd. reports results for the quarter ended June 30 - Earnings Summary
Biohaven Q2 net loss narrows on lower R&D spend
Biohaven gains as jury awards damages in Yale trade secret lawsuit
Brief: Biohaven - Completes Enrollment In Rise3 Pivotal Phase 2/3 Focal Epilepsy Study With Opakalim
Acting US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
Biohaven rises after completing enrollment in mid-stage obesity drug trial
Brief: Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Biohaven Q4 net loss narrows
U.S. STOCKS ON THE MOVE-Target, natgas firms, copper miners